MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted byTP53Mutation in Preclinical Models of Colorectal Cancer
- 14 December 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (24) , 5499-5510
Abstract
Purpose: PI3K pathway activation occurs in concomitance with RAS/BRAF mutations in colorectal cancer, limiting the sensitivity to targeted therapies. Several clinical studies are being conducted to test the tolerability and clinical activity of dual MEK and PI3K pathway blockade in solid tumors. Experimental Design: In the present study, we explored the efficacy of dual pathway blockade in colorectal cancer preclinical models harboring concomitant activation of the ERK and PI3K pathways. Moreover, we investigated if TP53 mutation affects the response to this therapy. Results: Dual MEK and mTORC1/2 blockade resulted in synergistic antiproliferative effects in cell lines bearing alterations in KRAS/BRAF and PIK3CA/PTEN. Although the on-treatment cell-cycle effects were not affected by the TP53 status, a marked proapoptotic response to therapy was observed exclusively in wild-type TP53 colorectal cancer models. We further interrogated two independent panels of KRAS/BRAF- and PIK3CA/PTEN-altered cell line– and patient-derived tumor xenografts for the antitumor response toward this combination of agents. A combination response that resulted in substantial antitumor activity was exclusively observed among the wild-type TP53 models (two out of five, 40%), but there was no such response across the eight mutant TP53 models (0%). Interestingly, within a cohort of 14 patients with colorectal cancer treated with these agents for their metastatic disease, two patients with long-lasting responses (32 weeks) had TP53 wild-type tumors. Conclusions: Our data support that, in wild-type TP53 colorectal cancer cells with ERK and PI3K pathway alterations, MEK blockade results in potent p21 induction, preventing apoptosis to occur. In turn, mTORC1/2 inhibition blocks MEK inhibitor–mediated p21 induction, unleashing apoptosis. Clin Cancer Res; 21(24); 5499–510. ©2015 AACR.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivoProceedings of the National Academy of Sciences, 2011
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS SignalingCancer Research, 2010
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal AntibodiesCancer Research, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescenceProceedings of the National Academy of Sciences, 2008
- Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damageNature, 2002